Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALBANY MOLECULAR RESEARCH INCAMRI · Entity 173403 | Director | May 10, 2017 | May 11, 2017 |
| Quince Therapeutics, Inc.QNCX · Entity 7403 | Director | June 04, 2025 | June 06, 2025 |
| RenovoRx, Inc.RNXT · Entity 6797 | Director | October 01, 2026 | October 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALBANY MOLECULAR RESEARCH INC
Report date May 10, 2017 · Filed May 11, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 51,845 |
Reported balance
After 2017-05-10 transaction · row 1
1 source rowRow 1 · 2017-05-10 · Exercise / conversion · Acquired 5,000 · Balance 51,845 |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $14.47 · Expires 2017-06-04 | Direct | 0 |
Reported balance
After 2017-05-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-05-10 · Exercise / conversion · Disposed 5,000 · Balance 0 F1: This option is currently exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: This option is currently exercisable.
Quince Therapeutics, Inc.
Report date June 04, 2025 · Filed June 06, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.09 · Expires 2035-06-04 | Direct | 27,000 |
Reported balance
After 2025-06-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-06-04 · Grant · Acquired 27,000 · Balance 27,000 F1: The shares subject to the option shall vest 100% on the one-year anniversary of the grant date. The Reporting Person elected to receive the stock options in lieu of the annual director cash retainer for 2025 provided for under the issuer's Outside Director Compensation Policy. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option shall vest 100% on the one-year anniversary of the grant date. The Reporting Person elected to receive the stock options in lieu of the annual director cash retainer for 2025 provided for under the issuer's Outside Director Compensation Policy.
RenovoRx, Inc.
Report date October 01, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.55 · Expires 2036-10-01 | Direct | 55,924 |
Reported balance
After 2026-10-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-10-01 · Grant · Acquired 55,924 · Balance 55,924 F1: The shares subject to the option vest in 12 equal monthly installments beginning on November 1, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option vest in 12 equal monthly installments beginning on November 1, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2026 Filed Oct 3, 2026 01:00 UTC | RenovoRx, Inc. RNXT · Entity 6797 | GrantStock Options (right to buy) · Derivative | 55,924 | $0.00 Strike: $1.55 | $0.00 |
DisclosureSEC source: 0001493152-26-045578 · ownership.xml · derivative · entry 1 RYAN UNA S · CIK 0001255349 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,924 Underlying: Common Stock · 55,924 shares Expires 2036-10-01 F1 · derivative.exercise_date: The shares subject to the option vest in 12 equal monthly installments beginning on November 1, 2026. Read SEC document |
| October 01, 2025 Filed Oct 3, 2025 00:17 UTC | RenovoRx, Inc. RNXT · Entity 6797 | GrantStock Options (right to buy) · Derivative | 47,640 | $0.00 Strike: $1.34 | $0.00 |
DisclosureSEC source: 0001493152-25-016758 · ownership.xml · derivative · entry 1 RYAN UNA S · CIK 0001255349 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,640 Underlying: Common Stock · 47,640 shares Expires 2035-10-01 F1 · derivative.exercise_date: The shares subject to the option vest in 12 equal monthly installments beginning on November 1, 2025. Read SEC document |
| June 04, 2025 Filed Jun 6, 2025 21:52 UTC | Quince Therapeutics, Inc. QNCX · Entity 7403 | GrantDirector Stock Option (Right to Buy) · Derivative | 27,000 | $0.00 Strike: $1.09 | $0.00 |
DisclosureSEC source: 0000912282-25-000625 · form4.xml · derivative · entry 1 RYAN UNA S · CIK 0001255349 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,000 Underlying: Common Stock · 27,000 shares Expires 2035-06-04 F1 · derivative.exercise_date: The shares subject to the option shall vest 100% on the one-year anniversary of the grant date. The Reporting Person elected to receive the stock options in lieu of the annual director cash retainer for 2025 provided for under the issuer's Outside Director Compensation Policy. Read SEC document |
| October 01, 2024 Filed Oct 2, 2024 20:30 UTC | RenovoRx, Inc. RNXT · Entity 6797 | GrantStock Options (right to buy) · Derivative | 25,099 | $0.00 Strike: $1.02 | $0.00 |
DisclosureSEC source: 0001493152-24-039214 · ownership.xml · derivative · entry 1 RYAN UNA S · CIK 0001255349 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,099 Underlying: Common Stock · 25,099 shares Expires 2034-10-01 F1 · derivative.exercise_date: The shares subject to the option vest in 12 equal monthly installments beginning on November 1, 2024. Read SEC document |
| June 05, 2024 Filed Jun 8, 2024 01:03 UTC | Quince Therapeutics, Inc. QNCX · Entity 7403 | GrantEmployee Stock Option (right to buy) · Derivative | 27,000 | $0.00 Strike: $0.82 | $0.00 |
DisclosureSEC source: 0001415889-24-016091 · form4-06082024_010657.xml · derivative · entry 1 RYAN UNA S · CIK 0001255349 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,000 Underlying: Common Stock · 27,000 shares Expires 2034-06-05 F1 · derivative.exercise_date: 100% of the shares subject to this stock option will vest on the one-year anniversary of the grant date. Read SEC document |
| October 01, 2023 Filed Oct 2, 2023 20:15 UTC | RenovoRx, Inc. RNXT · Entity 6797 | GrantStock Options (right to buy) · Derivative | 25,099 | $0.00 Strike: $1.33 | $0.00 |
DisclosureSEC source: 0001493152-23-035036 · ownership.xml · derivative · entry 1 RYAN UNA S · CIK 0001255349 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,099 Underlying: Common Stock · 25,099 shares Expires 2033-10-01 F1 · derivative.exercise_date: The shares subject to the option vest in 12 equal monthly installments beginning on November 1, 2023 Read SEC document |
| May 24, 2023 Filed May 26, 2023 21:50 UTC | Quince Therapeutics, Inc. QNCX · Entity 7403 | GrantStock Option (right to buy) · Derivative | 27,000 | $0.00 Strike: $1.58 | $0.00 |
DisclosureSEC source: 0001209191-23-032679 · doc4.xml · derivative · entry 1 RYAN UNA S · CIK 0001255349 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,000 Underlying: Common Stock · 27,000 shares Expires 2033-05-23 F1 · derivative.exercise_date: The shares subject to the stock option shall vest in equal annual installments over the three-year period following the grant date of May 24, 2023. Read SEC document |
| October 01, 2022 Filed Oct 4, 2022 20:44 UTC | RenovoRx, Inc. RNXT · Entity 6797 | GrantStock Option (right to buy) · Derivative | 25,099 | $0.00 Strike: $2.02 | $0.00 |
DisclosureSEC source: 0001209191-22-052309 · doc4.xml · derivative · entry 1 RYAN UNA S · CIK 0001255349 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,099 Underlying: Common Stock · 25,099 shares Expires 2032-10-01 F1 · derivative.exercise_date: The shares subject to the option vest in 12 equal monthly installments beginning on November 1, 2022. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 00:45 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | GrantStock Option (right to buy) · Derivative | 27,000 | $0.00 Strike: $3.23 | $0.00 |
DisclosureSEC source: 0001209191-22-035674 · doc4.xml · derivative · entry 1 RYAN UNA S · CIK 0001255349 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,000 Underlying: Common Stock · 27,000 shares Expires 2032-06-07 F1 · derivative.exercise_date: 100% of the shares subject to the stock option shall vest in full on the one-year anniversary of the grant date of June 8, 2022. Read SEC document |
| April 22, 2022 Filed Jun 24, 2026 21:20 UTC | RenovoRx, Inc. RNXT · Entity 6797 | OtherCommon Stock | 16,206 | $1.62 | $26,278.03 |
DisclosureSEC source: 0001493152-26-029958 · ownership.xml · nonDerivative · entry 4 RYAN UNA S · CIK 0001255349 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · The Una S. Ryan Revocable Trust Disclosed balance after: 97,165 F2 · kind: Reflects distribution from Golden Seeds Venture Fund GP, of which the reporting person is a non-managing member. Read SEC document |
| April 22, 2022 Filed Jun 24, 2026 21:20 UTC | RenovoRx, Inc. RNXT · Entity 6797 | OtherCommon Stock | 26,838 | $0.93 | $24,999.60 |
DisclosureSEC source: 0001493152-26-029958 · ownership.xml · nonDerivative · entry 3 RYAN UNA S · CIK 0001255349 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · The Una S. Ryan Revocable Trust Disclosed balance after: 80,959 F2 · kind: Reflects distribution from Golden Seeds Venture Fund GP, of which the reporting person is a non-managing member. Read SEC document |
| March 10, 2022 Filed Mar 14, 2022 20:53 UTC | RenovoRx, Inc. RNXT · Entity 6797 | GrantStock Option (right to buy) · Derivative | 4,582 | $0.00 Strike: $3.17 | $0.00 |
DisclosureSEC source: 0001209191-22-018500 · doc4.xml · derivative · entry 1 RYAN UNA S · CIK 0001255349 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,582 Underlying: Common Stock · 4,582 shares Expires 2032-03-10 F1 · derivative.exercise_date: The shares subject to the option vest in twelve equal monthly installments beginning on November 1, 2021. Read SEC document |
| March 03, 2022 Filed Jun 24, 2026 21:20 UTC | RenovoRx, Inc. RNXT · Entity 6797 | OtherCommon Stock | 6,332 | $3.95 | $25,011.40 |
DisclosureSEC source: 0001493152-26-029958 · ownership.xml · nonDerivative · entry 2 RYAN UNA S · CIK 0001255349 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · The Una S. Ryan Revocable Trust Disclosed balance after: 54,121 F1 · kind: Reflects distribution from Astria Fund, of which the reporting person is a non-managing member. Read SEC document |
| March 03, 2022 Filed Jun 24, 2026 21:20 UTC | RenovoRx, Inc. RNXT · Entity 6797 | OtherCommon Stock | 47,789 | $4.19 | $200,235.91 |
DisclosureSEC source: 0001493152-26-029958 · ownership.xml · nonDerivative · entry 1 RYAN UNA S · CIK 0001255349 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · The Una S. Ryan Revocable Trust Disclosed balance after: 47,789 F1 · kind: Reflects distribution from Astria Fund, of which the reporting person is a non-managing member. Read SEC document |
| October 01, 2021 Filed Oct 5, 2021 20:46 UTC | RenovoRx, Inc. RNXT · Entity 6797 | GrantStock Option (right to buy) · Derivative | 11,154 | $0.00 Strike: $5.91 | $0.00 |
DisclosureSEC source: 0001209191-21-059477 · doc4.xml · derivative · entry 1 RYAN UNA S · CIK 0001255349 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,154 Underlying: Common Stock · 11,154 shares Expires 2031-10-01 F1 · derivative.exercise_date: The shares subject to the option vest in 12 equal monthly installments beginning on November 1, 2021. Read SEC document |
| June 16, 2021 Filed Jun 17, 2021 23:29 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | GrantStock Option (right to buy) · Derivative | 11,029 | $0.00 Strike: $50.56 | $0.00 |
DisclosureSEC source: 0001209191-21-041716 · doc4.xml · derivative · entry 1 RYAN UNA S · CIK 0001255349 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,029 Underlying: Common Stock · 11,029 shares Expires 2031-06-15 F1 · derivative.exercise_date: 100% of the shares subject to the stock option shall vest in full on the one-year anniversary of the grant date of June 16, 2021. Read SEC document |
| June 08, 2020 Filed Jun 10, 2020 00:18 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | GrantStock Option (Right to Buy) · Derivative | 11,029 | $0.00 Strike: $41.73 | $0.00 |
DisclosureSEC source: 0001209191-20-035423 · doc4.xml · derivative · entry 1 RYAN UNA S · CIK 0001255349 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,029 Underlying: Common Stock · 11,029 shares Expires 2030-06-07 F1 · derivative.exercise_date: This option shall fully vest on the one-year anniversary of the grant date, subject to the reporting person's continued services as a member of the board of directors of Cortexyme, Inc. through such vesting date. Read SEC document |
| May 13, 2019 Filed Mar 12, 2020 20:43 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | PurchaseCommon Stock | 2,875 | $17.00 | $48,875.00 |
DisclosureSEC source: 0001209191-20-018550 · doc4.xml · nonDerivative · entry 1 RYAN UNA S · CIK 0001255349 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Una S. Ryan Revocable Trust Disclosed balance after: 2,875 F1 · ownership.nature: Shares reported herein are held of record by the Una S. Ryan Revocable Trust. Ms. Ryan is one of the trustees of the Una S. Ryan Revocable Trust, and has shared voting and dispositive power with respect to the shares held of record by the Una S. Ryan Revocable Trust. Read SEC document |
| May 10, 2017 Filed May 11, 2017 16:05 UTC | ALBANY MOLECULAR RESEARCH INC AMRI · Entity 173403 | Exercise / conversionOption to Purchase Common Stock · Derivative | 5,000 | $14.47 Strike: $14.47 | $72,350.00 |
DisclosureSEC source: 0001638599-17-000438 · doc4_4697.xml · derivative · entry 2 RYAN UNA S · CIK 0001255349 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2017-06-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option is currently exercisable. Read SEC document |
| May 10, 2017 Filed May 11, 2017 16:05 UTC | ALBANY MOLECULAR RESEARCH INC AMRI · Entity 173403 | Exercise / conversionCommon Stock | 5,000 | $14.47 | $72,350.00 |
DisclosureSEC source: 0001638599-17-000438 · doc4_4697.xml · nonDerivative · entry 1 RYAN UNA S · CIK 0001255349 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,845 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 08, 2017 Filed Feb 10, 2017 16:05 UTC | ALBANY MOLECULAR RESEARCH INC AMRI · Entity 173403 | GrantOption to Purchase Common Stock · Derivative | 9,358 | $0.00 Strike: $18.41 | $0.00 |
DisclosureSEC source: 0001638599-17-000190 · doc4_4518.xml · derivative · entry 2 RYAN UNA S · CIK 0001255349 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,358 Underlying: Common Stock · 9,358 shares Expires 2027-02-08 F1 · derivative.exercise_date: Option is exercisable as to 1/3rd of the shares annually on the anniversary date of the grant for each of the next three years. Read SEC document |
| February 08, 2017 Filed Feb 10, 2017 16:05 UTC | ALBANY MOLECULAR RESEARCH INC AMRI · Entity 173403 | GrantCommon Stock | 3,802 | $0.00 | $0.00 |
DisclosureSEC source: 0001638599-17-000190 · doc4_4518.xml · nonDerivative · entry 1 RYAN UNA S · CIK 0001255349 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,845 Read SEC document |
| October 05, 2016 Filed Oct 6, 2016 16:30 UTC | ALBANY MOLECULAR RESEARCH INC AMRI · Entity 173403 | Exercise / conversionOption to Purchase Common Stock · Derivative | 5,000 | $11.83 Strike: $11.83 | $59,150.00 |
DisclosureSEC source: 0001638599-16-001445 · doc4_4254.xml · derivative · entry 3 RYAN UNA S · CIK 0001255349 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2016-10-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option is currently exercisable. Read SEC document |
| October 05, 2016 Filed Oct 6, 2016 16:30 UTC | ALBANY MOLECULAR RESEARCH INC AMRI · Entity 173403 | Tax withholdingCommon Stock | 3,498 | $16.91 | $59,151.18 |
DisclosureSEC source: 0001638599-16-001445 · doc4_4254.xml · nonDerivative · entry 2 RYAN UNA S · CIK 0001255349 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,043 F1 · kind: Consists of shares withheld to pay exercise price. Read SEC document |
| October 05, 2016 Filed Oct 6, 2016 16:30 UTC | ALBANY MOLECULAR RESEARCH INC AMRI · Entity 173403 | Exercise / conversionCommon Stock | 5,000 | $11.83 | $59,150.00 |
DisclosureSEC source: 0001638599-16-001445 · doc4_4254.xml · nonDerivative · entry 1 RYAN UNA S · CIK 0001255349 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,541 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.